Table 1.
Disease
|
Indication(s) for CLKT
|
Monogenic diseases with primary hepatic expression without significant parenchymal damage | |
Atypical hemolytic-uremic syndrome | Renal failure and alternative complement pathway activity |
AIP | Renal failure and recurrent medically non-responsive AIP attacks |
Primary hyperoxaluria | Renal failure and metabolic control of the disease |
Homozygous protein C deficiency | Renal failure and coagulation control |
Hereditary complement C3 deficiency | Renal failure and risk reduction of recurrent infections (?) |
Monogenic diseases with primary hepatic expression with parenchymal damage | |
Alpha-1-antitrypsin deficiency | Renal failure and liver failure (cirrhosis) |
Glycogen storage disease | Renal failure with hepatocellular adenomatosis/carcinoma and metabolic control of the disease |
Monogenic diseases with hepatic and extrahepatic manifestation | |
Nephronophthisis associated with liver fibrosis | Renal failure and liver failure (cirrhosis) |
Lecithin cholesterol acyl transferase deficiency | Renal failure and metabolic control of disease |
Methylmalonic acidemia | Renal failure and metabolic decompensation |
Other | |
Antibody mediated rejection of the kidney | Renal failure and in the presence of positive CDC cross-match (?) |
CLKT: Combined liver and kidney transplantation; AIP: Acute intermittent porphyria; CDC: Complement-dependent cytotoxicity.